Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN). Sole...

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN)

Shares in Soleno Therapeutics ($SLNO) zoomed 28% higher in pre-market trading on reports that it could be bought for $2.5 billion by peer Neurocrin...

M&A News: Soleno Therapeutics Stock (SLNO) Surges 28% as Neurocrine Biosciences Lines up $2.5B Deal

Soluna Holdings ( ($SLNH) ) has provided an announcement. On April 1, 2026, an indirect Soluna Holdings subsidiary acquired 100% of Briscoe Wind Fa...

Soluna Expands Portfolio with Briscoe Wind Farm Acquisition

An update from Southland Holdings ( ($SLND) ) is now available. On March 27, 2026, American Bridge Company entered into a settlement agreement with...

Southland Settles Convention Center Dispute, Seeks Financing Accord

Stabilis Solutions ( ($SLNG) ) has shared an update. On March 31, 2026, Stabilis GDS terminated a previously announced 10-year LNG supply agreement...

Stabilis Solutions Terminates Key Galveston LNG Supply Agreement

In March 2025, the company celebrated FDA approval and touted VYKAT XR as safe, effective, and positioned for a strong commercial launch.&nbsp; Inv...

Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Disclosures and Stock Drop

Southland Holdings, Inc. (SLND) has disclosed a new risk, in the Litigation & Legal Liabilities category. Southland Holdings, Inc. faces heightened...

Litigation Overhang and Claim Strategies Raise Financial and Operational Risks for Southland Holdings

Important Notice Regarding Alleged DCCR Safety Data Misrepresentations NEW YORK, March 26, 2026 — Levi & Korsinsky, LLP notifies investors in Solen...

SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks: Levi & Korsinsky

In a report released yesterday, from Citi maintained a Buy rating on Stella International Holdings Limited, with a price target of HK$15.00. In add...

Citi Reaffirms Their Buy Rating on Stella International Holdings Limited (SLNLF)

Soleno (SLNO) promoted VYKAT XR as the first approved treatment for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder. Com...

Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Concealment in VYKAT XR Drug Launch

Stella International Holdings Limited ( ($HK:1836) ) has provided an announcement. Stella International Holdings Limited has declared a final ordin...

Stella International Declares HKD 0.37 Final Dividend for 2025

Stella International Holdings Limited ( ($HK:1836) ) has provided an update. Stella International Holdings Limited has declared a special cash divi...

Stella International Declares Special Cash Dividend for FY2025

Analysts have been eager to weigh in on the Energy sector with new ratings on Stabilis Solutions (SLNG – Research Report) and Solaris Energy Infras...

Analysts Conflicted on These Energy Names: Stabilis Solutions (SLNG) and Solaris Energy Infrastructure (SEI)

In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Soleno Therapeutics, with a price target of $123.00. A...

Cantor Fitzgerald Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)

Soluna Holdings ( ($SLNH) ) has issued an announcement. On March 10, 2026, Soluna issued a monthly update detailing February 2026 operating results...

Soluna Reports February Operations, Advances Green Data Centers

Chardan Capital analyst Keay Nakae maintained a Buy rating on Silence Therapeutics on March 5 and set a price target of $35.00. According to TipRan...

Current Quarter	$-0.33	Next Quarter	$-0.39
Current Year	$-1.04	Next Year	$-1.37
QoQ Growth	-18.2%	YoY Growth	-31.7%
3Y EPS CAGR	-115.4%	Target Price	$32.80
Consensus	Buy	Upside	+462.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$5.84	+4.20%	252.91K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$5.84	+4.2%	252.91K
3
4
5
6

SLN

SLN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Silence Therapeutics Plc Data in Excel

Get Silence Therapeutics Plc Data in Excel